Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Therapy De-intensification with iGlarLixi
2020-003715-94Phase 4Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Institute for Clinical and Experimental Medicine. Primary endpoint: Change in HbA1c. Started Oct 2020; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-003715-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003715-94.